Celgene price target raised to $104 from $94 at Jefferies Jefferies raised its estimates and price target for Celgene citing the company's new 2017 guidance, which the firm says reflects stronger than expected operating margin leverage. Jefferies keeps a Buy rating on Celgene, which was upgraded this morning at both RBC Capital and Piper Jaffray.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.